MARCO REFERENCIAL, TEÓRICO Y CONCEPTUAL
DE LA FORMACIÓN Y LA CAPACITACIÓN
2.5.9.1. Las competencias en la selección y capacitación:
should be further explored in a large prospective randomized trial with focus on patients presenting with anemia.
74
References
1 Harrison L, Shasha D, Shiaova L, White C, Ramdeen B, Portenoy R. Prevalence of anemia in cancer patients undergoing radiation therapy. Semin Oncol 2001;28:54-9.
2 Grau C, Overgaard J. Significance of hemoglobin concentration for treatment outcome. In: Molls M, Vaupel P, editors. Blood perfusion and microenvironment of human tumors. Berlin-Heidelberg-New-York, Germany: Springer-Verlag; 1998. p. 101-12.
3 Hoff CM, Lassen P, Eriksen JG, Hansen HS, Specht L, Overgaard M, et al: Does transfusion improve the outcome for HNSCC patients treated with radiotherapy? – Results from the randomized DAHANCA 5 and 7 trials. Acta Oncol 2011;50:1006-14.
4 Henke M, Sindlinger F, Ikenberg H, Gerds T, Schumacher M. Blood hemoglobin level and treatment outcome of early breast cancer. Strahlenther Onkol 2004;180:45-51.
5 Henke M, Laszig R, Rübe C, Schäfer U, Haase KD, Schilcher B, et al. Erythropoietin to treat head and neck cancer patients with anemia undergoing radiotherapy: randomized, double-blind, placebo- controlled trial. Lancet 2003;362:1255-60.
6 Leyland-Jones B: Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003; 4:459-60.
7 Lambin P, Ramaekers BL, van Mastrigt GA, van den Ende P, de Jong J, De Ruysscher DK, et al. Erythropoietin as an adjuvant treatment with (chemo) radiation therapy for head and neck cancer (review). Cochrane Database Syst Rev 2009;3:1-30.
8 Hoogsteen IJ, Pop LA, Marres HA, Merkx MA, van den Hoogen FJ, van der Kogel AJ, et al. Oxygen- modifying treatment with ARCON reduces the prognostic significance of hemoglobin in squamous cell carcinoma of the head and neck. Int J Radiat Biol Phys 2006;64:83-89.
9 Kaanders JH, Bussink J, van der Kogel AJ: ARCON: a novel biology-based approach in radiotherapy. Lancet Oncol 2002;3:728-37.
10 Janssens GO, Terhaard CH, Doornaert PA, Bijl HP, van den Ende P, Chin A, et al. Acute toxicity profile and compliance to ARCON for clinical stage T2-4 laryngeal cancer: results of a phase III randomized trial. Int J Radiat Oncol Biol Phys 2012;82:532-38.
11 Janssens GO, Rademakers SE, Terhaard CH, Doornaert PA, Bijl HP, van den Ende P, et al. Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: Results of a phase III randomized trial. J Clin Oncol 2012;30:1777-82.
12 Henk JM, Kunkler PB, Smith CW: Radiotherapy and hyperbaric oxygen in head and neck cancer. Final report of first controlled clinical trial. Lancet 1977;2:101-3.
13 Haustermans K, van der Kogel AJ, Vanacker B, van der Schueren E. Influence of combined use of nicotinamide and carbogen on rat spinal cord radiation tolerance. Radiother Oncol 1994;31:123-8. 14 Hoogsteen IJ, Lok J, Marres HA, Takes RP, Rijken PF, van der Kogel AJ, et al. Hypoxia in larynx
carcinomas assessed by pimonidazole binding and the value of CA-IX and vascularity as surrogate markers of hypoxia. Eur J Cancer 2009;45:2906-14.
15 Vaupel P: Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis. Oncologist 2008;13:21-6.
16 Becker A, Stadler P, Lavey RS, Hänsgen G, Kuhnt T, Lautenschlaäger C, et al. Severe anemia is associated with poor tumor oxygenation in head and neck squamous cell carcinomas. IntJ Radiat Oncol Biol Phys 2000;46:459-66.
17 Henke M, Mattern D, Pepe M, Bezay C, Weissenberger C, Werner M, et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol 2006;24:4708-13.
18 Varlotto J, Stevenson MA: Anemia, tumor hypoxemia, and the cancer patient. Int J Radiat Oncol Biol Phys 2005;63:25-36.
19 Prosnitz RG, Yao B, Farrell CL, Clough R, Brizel DM. Pretreatment anemia is correlated with reduced effectiveness of radiation and concurrent chemotherapy in advanced head and neck cancer. Int J Radiat Oncol Biol Phys 2005;61:1087-95.
75
ARCON and Cancer-Related Anemia
4
20 Denis F, Garaud P, Bardet E, Alfonsi M, Sire C, Germain T, et al. Final results of the 94-01 French headand neck oncology and radiotherapy group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 2004;22:69-76. 21 Hirst DG: Anemia: a problem or an opportunity in radiotherapy? Int J Radiat Biol Phys 1986;12:2009-17. 22 Tannock IF. Effects of pO2 on cell proliferation kinetics. In: Bond VP, Suit HD, Marcial V, editors. Time and
dose relationschips in radiation biology as applied to radiotherapy. Upton, Brookhaven National Laboratory; 1970. p. 215-24.
23 Hirst DG, Wood PJ: The adaptive response of mouse tumors to anemia and retransfusion. Int J Radiat Biol Relat Stud Phys Chem Med 1987;51:597-609.
24 Overgaard J: Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck: A systematic review and meta-analysis. Radiother Oncol 2011;100:22-32.
25 Dische S, Anderson PJ, Sealy R, Watson ER. Carcinoma of the cervix – anaemia, radiotherapy and hyperbaric oxygen. Br J Radiol 1983;56:251-5.
26 McCormack M, Nias AH, Smith E: Chronic anaemia, hyperbaric oxygen and tumour radiosensitivity. Br J Radiol 1990;63:752-9.
27 Harrison L, Blackwell K: Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy? Oncologist 2004;9:31-40.
28 Kelleher DK, Matthiensen, Thews O, Vaupel P. Blood flow, oxygenation, and bioenergetic status of tumors after erythropoietin treatment in normal and anemic rats. Cancer Res 1996;56:4728-34. 29 Nordsmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P, et al. Prognostic value of tumor
oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 2005;77:18-24.
30 Rudat V, Vanselow B, Wollensack P, Bettscheider C, Osman-Ahmet S, Eble MJ, et al. Repeatability and prognostic impact of the pretreatment pO2 histography in patients with advanced head and neck cancer.
Radiother Oncol 2000;57:31-7.
31 Kim JW, Dang CV. Cancer’s molecular sweet tooth and the Warburg effect. Cancer Res 2006;66:8927-30. 32 Meijer TW, Kaanders JH, Span PN, Bussink J. Targeting hypoxia, HIF-1 and tumor glucose metabolism
to improve radiotherapy efficacy. Clin Cancer Res 2012;18:5585-94.
33 Bron D, Meuleman N, Mascaux C. Biological basis of anemia. Semin Oncol 2001;28:1-6.
34 Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349:2091-98.
Geert O. Janssens Liselotte W. van Bockel Patricia A. Doornaert Hendrik P. Bijl Piet van den Ende Martin A. de Jong Guido B. van den Broek Berit M. Verbist
Chris H. Terhaard Paul N. Span
Johannes H. Kaanders